About DeepCure
DeepCure is a Healthcare company based in Boston (United States) founded in 2018 by Thrasyvoulos Thras Karydis, Joseph Jacobson, and Kfir Schreiber. It operates as a developer of novel small molecule therapies for immune diseases. DeepCure has raised $64.6 million across 2 funding rounds from investors including IAG Capital Partners, Morningside and TLV Partners. Its chief executive is Kfir Schreiber. DeepCure offers products and services including DC-15442 and Inspired Chemistryâ„¢ Platform. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development.
Company details
DeepCure was founded in 2018 and is based in Boston, United States. Small molecule therapies for immune diseases are developed through an automated chemical synthesis platform. Preclinical and clinical-stage candidates are advanced in the pipeline to address autoimmune disorders and other immune-mediated conditions. Collaborations with leading researchers are maintained to support therapeutic development in the biotechnology sector.
- Headquarters Boston, United States
- Founders Thrasyvoulos Thras Karydis, Joseph Jacobson, Kfir Schreiber
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website deepcure.com
- Social LinkedIn X
- Legal Name Deepcure
- Total Equity Funding$64.6M (USD)
in 2 rounds
- Latest Funding Round$24.6M (USD), Series A
Apr 2024
- InvestorsIAG Capital Partners
& 4 more
Products & Services of DeepCure
DeepCure offers a comprehensive portfolio of products and services, including DC-15442 and Inspired Chemistry™ Platform.
This candidate is developed as an oral STAT6 inhibitor that has been shown to achieve 100% in vivo inhibition of pSTAT6 and comparable efficacy to other treatments in disease models.
This platform is employed for automated chemical synthesis and has been utilized to generate top-selling drugs and diverse analogs in the context of immune disease research.
Funding Insights of DeepCure
DeepCure has successfully raised a total of $64.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $24.6 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $64.6M
- Total Rounds 2
- Last Round Series A — $24.6M
- First Round $40M
(Nov 2021)
- Investors Count 5
All 2 funding rounds of DeepCure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $24.6M | Series A | – | IAG Capital Partners | – |
| Nov 2021 | $40M | Series A | – | Morningside |
5 investors in total: 5 institutional.
Investors in DeepCure
DeepCure has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include IAG Capital Partners, Morningside and TLV Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are provided by IAG Capital Partners. | – | iagcapitalpartners.com | Charleston, USA | |
Multiple sectors are invested in by Morningside, a VC fund. | – | morningside.com | Newton, United States | |
VC firm investing in early stage startups in Israel & the US | – | tlv.partners | Tel Aviv, Israel | |
Deep technologies are targeted for venture capital investments. | – | sapirvp.com | Jerusalem, Israel | |
- | – | benongroupltd.tcc.mode | - |
Investor details for DeepCure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DeepCure
3 people are tracked at DeepCure (3 in leadership).
| Name | Role | Group |
|---|---|---|
Thrasyvoulos Thras Karydis | Co-Founder & CTO | Leadership |
Joseph Jacobson | Co-Founder | Leadership |
Kfir Schreiber | Co-Founder & CEO | Leadership |
Complete people profiles for DeepCure
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DeepCure
3 dated milestones of DeepCure across 6 years, from founding to its latest funding, stage changes and deals.
- Founded DeepCure is founded.
- Funding First funding round of $40.0M.
- Funding Latest funding round, Series A, of $24.6M.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as DeepCure (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DeepCure
DeepCure was founded in 2018 and raised its 1st funding round 3 years after it was founded.
DeepCure is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Kfir Schreiber is the current CEO of DeepCure. They have also founded this company.
DeepCure is a funded company, having raised a total of $64.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Nov 2021.
DeepCure was founded in 2018 and is based in Boston, United States. Small molecule therapies for immune diseases are developed through an automated chemical synthesis platform. Preclinical and clinical-stage candidates are advanced in the pipeline to address autoimmune disorders and other immune-mediated conditions. Collaborations with leading researchers are maintained to support therapeutic development in the biotechnology sector.
DeepCure offers DC-15442 and Inspired Chemistryâ„¢ Platform.
DeepCure has 5 investors. Key investors include IAG Capital Partners, Morningside, TLV Partners, Sapir Venture Partners, and Benon Group.
DeepCure operates through Deepcure.